Table of Contents
- Overview of Loratadine trials
- Conditions studied
- Trial design, phases, and who can join
- Main endpoints and what the studies measure
- How Loratadine is used in these studies
- What these trials mean for patients
Overview of Loratadine trials
Loratadine appears in a range of interventional clinical trials, mostly in studies about allergy symptoms and symptom control.[1] In the source data, it is used in trials for allergic rhinitis, rhinoconjunctivitis, chronic spontaneous urticaria, pruritus, lymphangioleiomyomatosis, Crigler-Najjar syndrome, and several other diseases.[2]
These studies are not all trying to answer the same question.[3] Some trials test whether Loratadine helps control symptoms, while others include it as a support medicine or as part of a treatment plan being compared with placebo or another active treatment.[4]
Conditions studied
Most of the Loratadine-related trials in the data are in allergic rhinitis and rhinoconjunctivitis, which are allergy problems that affect the nose and sometimes the eyes.[5] These studies include seasonal allergies caused by grass pollen, birch pollen, olive pollen, and house dust mite allergy.[6]
Other trials study chronic spontaneous urticaria, which means hives that happen without a known cause, and pruritus, which means itching.[7] Loratadine also appears in trials for less common conditions such as lymphangioleiomyomatosis, a rare lung disease, and Crigler-Najjar syndrome, a rare disorder involving high bilirubin levels.[1]
In the oncology studies, Loratadine is listed among several medicines used in adults with large B-cell lymphoma during treatment plans that include other drugs.[8] Another trial includes Loratadine in a study of anti-GBM antibody disease, also called Goodpasture disease, which affects the kidneys.[9]
Trial design, phases, and who can join
The studies are mainly Phase 2, Phase 3, and Phase 4 trials.[10] Phase 2 trials are usually smaller and look closely at early signs of benefit and safety, while Phase 3 and Phase 4 trials are larger and compare treatments in broader patient groups.[11]
Many of the allergy studies include adolescents, adults, or children, depending on the trial.[4] For example, one grass pollen trial is in paediatric subjects, while other allergy studies are in adults with chronic itching or adults with house dust mite or birch pollen allergy.[10]
The enrollment sizes vary widely, from very small studies such as the Crigler-Najjar trial with 3 participants to large allergy trials with more than 500 participants.[2] This shows that some studies are early or rare-disease studies, while others are larger confirmatory trials.[5]
Main endpoints and what the studies measure
The main endpoint in many allergy trials is a symptom score called CSMS, which stands for Combined Symptom and Medication Score.[5] This score combines how bad the symptoms are and how much rescue medicine the participant needs.[11]
In the house dust mite, birch pollen, grass pollen, and olive pollen studies, the trials compare the active treatment with placebo by looking at CSMS or similar symptom scores during the peak pollen period or the last weeks of treatment.[6] The goal is to see whether the active treatment gives better symptom control than placebo during the worst allergy season.[10]
In the chronic spontaneous urticaria study, the main endpoint is the change in UAS7, which is a weekly hives score, and the study also measures safety events such as adverse events and serious adverse events.[7] In the pruritus study, the main endpoint is improvement in the worst-itch numerical rating scale, which measures how severe the itching is.[4]
Some non-allergy trials use disease-specific endpoints. The Crigler-Najjar study measures serum total bilirubin, the lymphangioleiomyomatosis trial measures adverse effects over 48 weeks, and the anti-GBM trial measures kidney function using eGFR at 6 months.[1] The large B-cell lymphoma studies measure cancer response or progression-free survival, which means the length of time before the disease gets worse or returns.[12]
How Loratadine is used in these studies
In some trials, Loratadine is the study medicine or part of the treatment being evaluated, such as in the lymphangioleiomyomatosis study and the chronic hives study.[1] In other trials, it is one of several medicines used to manage symptoms during allergen immunotherapy studies, where the main treatment is the allergen vaccine or extract rather than Loratadine itself.[11]
The source data also shows different brand names and related medicines listed alongside Loratadine, such as Loratadina NORMON, Lorano akut, Loratadin-ratiopharm, and other local product names.[13] These names refer to the same universal drug name, Loratadine, while the brand names can differ by country or study site.[13]
What these trials mean for patients
For patients, these trials show that Loratadine is being studied in several different ways, not only for common allergy symptoms but also in special research settings.[4] Most of the research is about whether it helps symptoms, how well it is tolerated in study settings, and how it fits into larger treatment plans.[5]
The studies use clear outcome measures such as symptom scores, itch scores, blood tests, urine tests, and kidney function tests, so researchers can compare results in a structured way.[1] Because the trials include different age groups and different diseases, the role of Loratadine is not the same in every study.[10]
